학술논문
Decreased Neurofilament L Chain Levels in Cerebrospinal Fluid and Tolerogenic Plasmacytoid Dendritic Cells in Natalizumab-Treated Multiple Sclerosis Patients – Brief Research Report
Document Type
article
Author
Adriel S. Moraes; Vinicius O. Boldrini; Alliny C. Dionete; Marilia D. Andrade; Ana Leda F. Longhini; Irene Santos; Amanda D. R. Lima; Veronica A. P. G. Silva; Rafael P. C. Dias Carneiro; Raphael P. S. Quintiliano; Breno B. Ferrari; Alfredo Damasceno; Fernando Pradella; Alessandro S. Farias; Charles P. Tilbery; Renan B. Domingues; Carlos Senne; Gustavo B. P. Fernandes; Felipe von Glehn; Carlos Otavio Brandão; Carla R. A. V. Stella; Leonilda M. B. Santos
Source
Frontiers in Cellular Neuroscience, Vol 15 (2021)
Subject
Language
English
ISSN
1662-5102
Abstract
BackgroundNeurofilament Light (NfL) chain levels in both cerebrospinal fluid (CSF) and serum have been correlated with the reduction of axonal damage in multiple sclerosis (MS) patients treated with Natalizumab (NTZ). However, little is known about the function of plasmacytoid cells in NTZ-treated MS patients.ObjectiveTo evaluate CSF NfL, serum levels of soluble-HLA-G (sHLA-G), and eventual tolerogenic behavior of plasmacytoid dendritic cells (pDCs) in MS patients during NTZ treatment.MethodsCSF NfL and serum sHLA-G levels were measured using an ELISA assay, while pDCs (BDCA-2+) were accessed through flow cytometry analyses.ResultsCSF levels of NfL were significantly reduced during NTZ treatment, while the serum levels of sHLA-G were increased. Moreover, NTZ treatment enhanced tolerogenic (HLA-G+, CD274+, and HLA-DR+) molecules and migratory (CCR7+) functions of pDCs in the peripheral blood.ConclusionThese findings suggest that NTZ stimulates the production of molecules with immunoregulatory function such as HLA-G and CD274 programmed death-ligand 1 (PD-L1) which may contribute to the reduction of axonal damage represented by the decrease of NfL levels in patients with MS.